Predictive genetic testing for cardiomyopathies

Zou, 2004, Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults, Am J Med, 116, 14, 10.1016/j.amjmed.2003.05.009 Maron, 2005, Distinguishing hypertrophic cardiomyopathy from athlete's heart: a clinical problem of increasing magnitude and significance, Heart, 91, 1380, 10.1136/hrt.2005.060962 Colan, 2007, Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry, Circulation, 115, 773, 10.1161/CIRCULATIONAHA.106.621185 Towbin, 2006, Incidence, causes, and outcomes of dilated cardiomyopathy in children, JAMA, 296, 1867, 10.1001/jama.296.15.1867 Lipshultz, 2003, The incidence of pediatric cardiomyopathy in two regions of the United States, N Engl J Med, 348, 1647, 10.1056/NEJMoa021715 Tardiff, 2005, Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes, Heart Fail Rev, 10, 237, 10.1007/s10741-005-5253-5 Ingles, 2005, Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling, J Med Genet, 42, e59, 10.1136/jmg.2005.033886 Van Driest, 2004, Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy, J Am Coll Cardiol, 44, 1903, 10.1016/j.jacc.2004.07.045 Richard, 2003, Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy, Circulation, 107, 2227, 10.1161/01.CIR.0000066323.15244.54 Watkins, 1995, Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy, N Engl J Med, 332, 1058, 10.1056/NEJM199504203321603 Watkins, 1992, Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy, N Engl J Med, 326, 1108, 10.1056/NEJM199204233261703 Karibe, 2001, Hypertrophic cardiomyopathy caused by a novel alpha-tropomyosin mutation (V95A) is associated with mild cardiac phenotype, abnormal calcium binding to troponin, abnormal myosin cycling, and poor prognosis, Circulation, 103, 65, 10.1161/01.CIR.103.1.65 Charron, 1998, Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene, Circulation, 97, 2230, 10.1161/01.CIR.97.22.2230 Niimura, 1998, Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy, N Engl J Med, 338, 1248, 10.1056/NEJM199804303381802 Maron, 2003, Sudden death in young athletes.[see comment], N Engl J Med, 349, 1064, 10.1056/NEJMra022783 Semsarian, 2002, The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model, J Clin Invest, 109, 1013, 10.1172/JCI200214677 Patel, 2001, Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy, Circulation, 104, 317, 10.1161/hc2801.094031 Lim, 2001, Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy, Circulation, 103, 789, 10.1161/01.CIR.103.6.789 Tsybouleva, 2004, Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy, Circulation, 109, 1284, 10.1161/01.CIR.0000121426.43044.2B 1995, Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. American Society of Human Genetics Board of Directors, American College of Medical Genetics Board of Directors, Am J Hum Genet, 57, 1233 van Langen, 2005, Preferences of cardiologists and clinical geneticists for the future organization of genetic care in hypertrophic cardiomyopathy: a survey, Clin Genet, 68, 360, 10.1111/j.1399-0004.2005.00502.x